KB-1091-01

Ifinatamab

Background

Ifinatamab deruxtecan (I-DXd; DS-7300) is a novel ADC that shows great promise as an anti-cancer agent. Comprised of an anti-B7-H3 antibody linked to the DNA topoisomerase I inhibitor, DXd, I-DXd has demonstrated impressive anti-tumor activity in preclinical cancer models that express B7-H3. Early clinical trials have also reported encouraging results, showing I-DXd to be effective in patients with advanced solid tumors who had undergone extensive prior treatment. The mechanism of ADCs relies on the compound's target-specific uptake, leading to cytotoxicity in tumors expressing the target antigen.

Specifications

Catalog Number:
KB-1091-01
Cell Line Name:
Ifinatamab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
B7-H3
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. WHO Drug Information. International Nonproprietary Names for Pharmaceutical.
Please enable JavaScript in your browser to complete this form.